These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30653127)

  • 1. Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study.
    Demelo-Rodríguez P; Galeano-Valle F; García-Fernández-Bravo I; Piqueras-Ruiz S; Álvarez-Sala-Walther L; Del Toro-Cervera J
    Medicine (Baltimore); 2019 Jan; 98(3):e14093. PubMed ID: 30653127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
    Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
    Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.
    Søgaard M; Nielsen PB; Skjøth F; Kjaeldgaard JN; Larsen TB
    Cancer Med; 2019 Mar; 8(3):1044-1053. PubMed ID: 30767432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
    Khorana AA; Berger JS; Wells PS; Seheult R; Ashton V; Laliberté F; Crivera C; Lejeune D; Schein J; Wildgoose P; Lefebvre P; Kaatz S
    Clin Ther; 2017 Jul; 39(7):1396-1408. PubMed ID: 28645879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
    Kingdon LK; Miller EM; Savage SA
    J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.
    Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI
    J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.